secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2023-09-18T23:59:59+00:00
Accession:  0000886163-23-000053
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand merges Pelican unit into Primrose Bio, retains 49.9% stake and milestone rights
--------------------------------------------------------------------------------

- Subsidiary Pelican Technology merged into Primrose Bio; Ligand owns 49.9% of the combined company.
- Ligand retains all existing Pelican Expression Technology royalties (RYLAZE, VAXNEUVANCE, V116, Teriparatide, Pneumosil, MenFive).
- Ligand contributed $15M for rights to 50% of development milestones from two prior Primordial Genetics contracts.
- Starting 2025, Ligand receives 25% of PeliCRM197 sales revenue above $3M and 35% of PeliCRM197 licensing revenue.
- Combined platform pairs Pelican Expression Technology with Primordial Genetics' Function Generator for synthetic biology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616323000053/0000886163-23-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616323000053/lgnd-20230918.htm
  HTML page:      https://secwatch.observer/filing/0000886163-23-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer